The relationship of TFPI, Lp(a), and oxidized LDL antibody levels in patients with coronary artery disease.
OBJECTIVE
The aim of the present study was to determine and correlate tissue factor pathway inhibitor (TFPI), lipoprotein (a) (Lp(a)), oxidized low-density lipoprotein (LDL) antibody (oLAB), and thiobarbituric acid reactive substances (TBARS; as a marker of lipid peroxidation) levels in patients with coronary artery disease (CAD) and in a control group.


METHODS
Peripheral blood samples from patients with coronary heart disease were provided by the Department of Cardiology. Serum oLAB, Lp(a), plasma total TFPI, and plasma-free TFPI levels were determined by ELISA. Serum TBARS levels were determined by a spectrophotometric method using thiobarbituric acid.


RESULTS
The CAD and the control group were matched for age and sex. Serum Lp(a), oLAB, and plasma total TFPI levels in patients with coronary heart disease were found to be significantly higher than in the control group (P < 0.001). But there was no difference in plasma-free TFPI levels between patients with CAD and the control group (P > 0.05). In patients with single (P < 0.05), double, and triple vessel (P < 0.01) disease, the mean serum Lp(a) levels were significantly higher than in the control group. On the other hand, in patients with single vessel disease (P < 0.05), double vessel disease (P < 0.05), and triple vessel disease (P < 0.001), plasma total TFPI levels were found to be significantly higher than in the control group. We also found a significant positive correlation (r = 0.28, P < 0.05) between serum Lp(a) and plasma total TFPI levels in CAD. In the patient group, TBARS, total cholesterol, triglyceride (TRG), and LDL cholesterol levels were found to be significantly higher than those in the control group. In addition, high-density lipoprotein (HDL) cholesterol levels were found to be significantly lower than the control group.


CONCLUSIONS
These results suggest that elevated plasma levels of total TFPI, Lp(a), and oLAB may be useful diagnostic and monitoring markers in patients with CAD.
Bilgen
Dilek
D
Department of Biochemistry, Cerrahpasa Medical Faculty, University of Istanbul, Turkey.
Sönmez
Hüseyin
H
Ekmekçi
Hakan
H
Ulutin
Turgut
T
Oztürk
Zeynep
Z
Kökoğlu
Emine
E
Bayram
Ciğdem
C
Soner
Ali
A
Domaniç
Nergiz
N
D000368:Aged; D000906:Antibodies / Q000097:blood* / Q000276:immunology; D015415:Biomarkers; D003324:Coronary Artery Disease / Q000097:blood* / Q000276:immunology; D005260:Female; D006801:Humans; D015227:Lipid Peroxidation; D017270:Lipoprotein(a) / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008077:Lipoproteins, LDL / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism
D000906:Antibodies; D015415:Biomarkers; D017270:Lipoprotein(a); D008074:Lipoproteins; D008077:Lipoproteins, LDL; D017392:Thiobarbituric Acid Reactive Substances; C051928:lipoprotein-associated coagulation inhibitor; C099252:oxidized low density lipoprotein